-

Axcella to Present at Upcoming Investor Conferences

Webcasts scheduled for February 26, March 9 and March 15

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will participate in the following upcoming investor conferences:

  • SVB Leerink 10th Annual Global Healthcare Conference: The company’s fireside chat will be webcast on February 26, 2021 at 9:20 a.m. ET.
  • H.C. Wainwright Global Life Sciences Conference: The company’s presentation will be webcast on March 9, 2021 at 7:00 a.m. ET.
  • 33rd Annual Roth Conference: The company’s fireside chat will be webcast on March 15, 2021 at 9:00 a.m. ET.

The audio webcasts will be accessible on the “Investors & News” section of the company’s website, www.axcellahealth.com, for 90 days following the presentations.

Internet Posting of Information

Axcella uses its website, www.axcellahealth.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the “Investors and News” section. Accordingly, investors should monitor this portion of the company’s website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

About Axcella

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. For more information, please visit www.axcellahealth.com.

Contacts

Jason Fredette
jfredette@axcellahealth.com
857.320.2236

Industry:

Axcella

NASDAQ:AXLA
Details
Headquarters: Cambridge, MA
CEO: William Hinshaw, Jr.
Employees: 60
Organization: PUB
Release Versions
English

Contacts

Jason Fredette
jfredette@axcellahealth.com
857.320.2236

More News From Axcella

Axcella Announces Reverse Stock Split Effective September 19, 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that its Board of Directors has approved a 1-for-25 reverse stock split of the Company’s common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time on September 18, 2023, after close of trading on The Na...

Axcella Granted Patent for Long COVID Fatigue Treatment

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,737,999 with claims covering methods of use of Candidate AXA1125, for treating a subject having post-acute sequelae of COVID-19 (PASC), a/k/a Long CO...

Axcella Reports Second Quarter Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced financial results for the second quarter ended June 30, 2023 and provided a business update. “Patients are seeking relief from Long COVID fatigue. Axcella’s proprietary composition of amino acids in AXA1125 in Long COVID fatigue i...
Back to Newsroom